The AIDS Advisory document recorded that heat-treated commercial factor products were available. On the subject, Professor Bloom stated that during the early 1980s, several observers noted that there appeared to be a reduced risk of HIV infection and/or immunological abnormalities in patients with haemophilia B compared to those with haemophilia A.